The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: AB Foods Reports Sales Rises Across Portfolio

Thu, 16th Jan 2020 08:03

(Alliance News) - Associated British Foods highlighted a string of trading updates from UK consumer companies on Thursday.

AB Foods said its outlook is unchanged following a good first quarter for fast fashion store chain Primark.

Group sales for the 16 weeks to January 4 were up 4% year-on-year at constant currency, and 3% ahead at actual rates.

Sales at high-street chain Primark were up 4.5% year-on-year at constant currency and 3.0% ahead at actual exchange rates. This was, however, "almost entirely" driven by an increase in selling space. The like-for-like performance improved, AB Foods said without specifying numbers, driven by a marked upturn in the eurozone.

In the UK, Primark sales were up 4.0% driven by new selling space and a "marginal" decline in like-for-like sales. Sales in the eurozone were up 5.1% with the improvement in like-for-like sales seen in the final quarter of the previous financial year continuing. The US also delivered like-for-like sales growth.

"As expected, operating profit margin in the period decreased, with the effect of purchases contracted at a stronger US dollar exchange rate than last year but partially mitigated by cost reductions in both the cost of goods and overheads," said AB Foods.

In the current financial year, AB Foods expects to open 18 new Primark stores, with its first store in eastern Europe, in Ljubljana, Slovenia exceeding expectations.

Elsewhere in the AB Foods portfolio, Sugar revenue was up 7% at constant currency and Grocery sales flat, while Agriculture revenue was 10% ahead of a year ago and Ingredients sales up 3%.

The stock was up 2.1% in early dealings Thursday.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 3.52 points at 7,646.32

----------

Hang Seng: up 0.2% at 28,824.69

Nikkei 225: closed up 0.1% at 23,933.13

DJIA: closed up 90.55 points, 0.3%, at 29,030.22

S&P 500: closed up 0.2% at 3,289.29

----------

GBP: firm at USD1.3039 (USD1.3024)

EUR: soft at USD1.1147 (USD1.1159)

Gold: up at USD1,552.91 per ounce (USD1,549.30)

Oil (Brent): up at USD64.34 a barrel (USD63.70)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Thursday's Key Economic Events still to come

0930 GMT UK Bank of England credit conditions survey

1000 CET France IEA oil market report

0830 EST US import and export price indices

0830 EST US advance monthly sales for retail & food services

0830 EST US initial jobless claims

1000 EST US manufacturing & trade: inventories & sales

1000 EST US NAHB housing market index

1030 EST US EIA weekly natural gas storage report

----------

The UK property market has been given a lift by the general election result, according to surveyors. The number of house sales taking place across the UK has increased for the first time in seven months, the Royal Institution of Chartered Surveyors report for December said. Agreed sales in London and East Anglia in particular saw an improvement, although sales reportedly weakened in Northern Ireland and Scotland. Inquiries from buyers are also now generally on the up, after previously falling back in November, the report found.

----------

Consumer prices in Germany rose by 1.4% on an average annual basis in 2019, the Federal Statistical Office of Germany said. The average year-on-year increase in 2019 was down on the 1.8% average rise seen in 2018. The deceleration was attributed to a marked slowdown in energy price inflation to 1.4% in 2019 from 4.6% in 2018. Turning to December, the annual German consumer price inflation rate was 1.5%, accelerating from 1.1% in November. December's reading marked the first acceleration since July.

----------

BROKER RATING CHANGES

----------

BARCLAYS CUTS GLAXOSMITHKLINE TO 'UNDERWEIGHT' (EQUAL WEIGHT) - PRICE TARGET 1650 PENCE

----------

JEFFERIES CUTS DIAGEO TO 'HOLD' (BUY) - PRICE TARGET 3600 PENCE

----------

BARCLAYS CUTS SPIRENT TO 'UNDERWEIGHT' ('EQUAL WEIGHT') - TARGET 190 (159) PENCE

----------

COMPANIES - FTSE 100

----------

Pearson said it met guidance in 2019 though predicts challenging trends in US Higher Education Courseware to continue. The educational publisher said underlying revenue was flat in 2019 and adjusted operating profit GBP590 million. US Higher Education Courseware revenue declined by 12%, though there was "modest" growth in digital revenue. Pearson said it expects the trends seen in the unit to continue, with heavy declines in print partially offset by modest growth in digital. For 2020, Pearson expects to deliver adjusted operating profit between GBP500 million to GBP580 million, including the 25% stake in Penguin Random House that it recently agreed to sell for USD675 million. Pearson said Chief Financial Officer Coram Williams will be leaving the company and will be replaced by Sally Johnson, deputy financial officer. Williams will step down from his position and from the board later this year.

----------

Whitbread said it delivered a "robust" third quarter despite challenging conditions in the UK. Total UK sales in the third quarter were up 0.3%, though fell 1.3% on a like-for-like basis. UK & International total sales growth was 1.0%. The start of the fourth quarter has seen more positive regional UK data due to lower comparators and the timing of Christmas, the company said, along with the continuation of the strong London market. However, "it is still early" in the fourth quarter and "a level of caution" remains on the UK hotel environment, Whitbread added. Looking into the 2021 financial year, Whitbread noted that the UK backdrop remains "uncertain" and sustained industry inflation continues. Whitbread said it will take a cautious approach to hotel demand and expects a net margin headwind of around GBP60 million, comprising wage inflation and ongoing investment, partially offset by its efficient programme.

----------

COMPANIES - FTSE 250

----------

Recruitment firm Hays expects a fall in first half revenue due to strikes in France, the bushfires in Australia, the UK general election, and a slowdown in activity in Germany. Hays said it expects operating profit for the first half of around GBP100 million, which would be down from GBP124.1 million a year ago. Group net fees for the second quarter, which ended December 31, fell by 7% on a headline basis and 4% like-for-like. Like-for-like net fees in its Temp and Perm businesses declined by 3% and 6% respectively. In Australia & New Zealand, net fees were down 7% like-for-like and Germany down 9%, while the UK & Ireland fell 4%.

----------

COMPANIES - OTHER MAIN MARKET AND AIM

----------

Seawave Investment - the firm which, according to Lekoil, brokered a loan to the Nigerian oil firm from fake Qatari investors - will address the matter, the Financial Times reported. Lekoil late Monday said it parted, "in good faith" with USD600,000 to Seawave which acted as an introducer to those "purporting to be the Qatar Investment Authority". At the start of January, Lekoil announced it agreed a USD184.0 million loan from QIA for drilling and development at the Ogo field off the coast of Nigeria. Seawave's Managing Partner Bismarck Abrafi told the newspaper that the company will respond to the allegations. "We will issue a full statement and everything will be clear," Abrafi told the FT.

----------

COMPANIES - INTERNATIONAL

----------

The Japanese lawyer nicknamed the "Razor" who was spearheading Carlos Ghosn's defence said Thursday he is quitting the case after his client skipped bail and fled Japan for Lebanon. Junichiro Hironaka's office issued a brief statement saying they had "filed with the Tokyo District Court letters of resignation for all lawyers...connected with all cases related to Carlos Ghosn". Hironaka, 74, who earned his nickname for sharp legal strategies and an enviable acquittal record, has said he was "dumbfounded" by Ghosn's escape, which he discovered via the media on the morning his client fled. Another one of Ghosn's legal team, Takashi Takano, has also thrown in the towel on the case, a source close to his office told AFP.

----------

Thursday's Shareholder Meetings

Cardiff Property

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.